BioVersys Initiates Phase 3 Trial for BV100 Antibiotic Following 50% Mortality Reduction in Phase 2
核心洞察
BioVersys (搜索) has initiated a global Phase 3 registration trial for BV100, a novel antibiotic targeting carbapenem-resistant Acinetobacter baumannii (搜索) infections in ventilator-associated bacterial pneumonia (搜索) patients.
Phase 2 data demonstrated a 50% relative reduction in all-cause mortality compared to best available therapy in patients with carbapenem-resistant Acinetobacter baumannii (搜索) infections.
The company completed a successful IPO raising CHF 76.7 million in February 2025, extending its cash runway to 2028 and marking the largest biotech IPO in Europe in five years.
BioVersys (搜索) AG has launched a global Phase 3 registration study for BV100, its lead antibiotic candidate targeting multi-drug resistant bacterial infections (搜索), following compelling Phase 2 survival data that demonstrated a 50% relative reduction in all-cause mortality. The Swiss biopharmaceutical company submitted clinical trial applications to regulatory authorities in December 2025, with first patient dosing expected in the coming months.
Strong Phase 2 Survival Benefit Drives Phase 3 Advancement
The Phase 3 trial builds on robust Phase 2 results showing BV100 treatment resulted in a 50% relative reduction in all-cause mortality in ventilator-associated bacterial pneumonia (搜索) (VABP) patients suffering from carbapenem-resistant Acinetobacter baumannii (搜索) (CRAB) infections compared with best available therapy. The treatment was generally safe and well tolerated across the patient population.
Following successful end-of-Phase 2 meetings with the US FDA and EMA Emergency Task Force, BioVersys (搜索) initiated the global registration program that will include clinical sites across the US, Europe, Latin America, Asia, and China. The Phase 3 study will employ a similar design to the successful Phase 2 trial, with topline data expected toward the end of the second half of 2027.
Expanded Global Development Program
The company has begun geographic expansion into China, with the first healthy volunteer dosed with BV100 in a mandatory Phase 1 trial. This trial precedes the inclusion of Chinese clinical sites by late 2026 into the global Phase 3 registration program.
Beyond the registrational Phase 3 program necessary for regulatory approval in the US, EU, and China, BioVersys (搜索) is planning a Phase 2b trial in a similar patient population. This study will compare BV100 to best available therapy instead of colistin, aiming to provide real-world evidence of clinical practices in settings with very high drug resistance levels.
The Phase 2b trial was selected for conduct and funding by ADVANCE-ID (搜索), a clinical trial network centered at the Saw Swee Hock School of Public Health, National University of Singapore. Wellcome (搜索) is contributing SGD 22 million (approximately USD 17 million or CHF 14 million) to ADVANCE-ID, significantly reducing BioVersys (搜索)' financial contribution. The Phase 2b trial is expected to start in the first half of 2026.
Financial Strength Following Record IPO
BioVersys (搜索) completed its initial public offering on the SIX Swiss Exchange on February 7, 2025, raising CHF 76.7 million in proceeds. The IPO marked the first biotech company IPO in Switzerland in seven years and the largest IPO in the past five years on any European exchange. The funding extends the company's cash runway to 2028, including completion of the BV100 Phase 3 trial in VABP, hospital-acquired bacterial pneumonia (搜索) (HABP), and bloodstream infections (搜索) (BSI).
Expanding Pipeline Through Strategic Partnerships
The company has established significant partnerships to advance its broader pipeline. BioVersys (搜索) entered into a global research collaboration and exclusive license option agreement with Japanese pharmaceutical leader Shionogi (搜索) for its BV500 (搜索) program targeting non-tuberculous mycobacteria (NTM) infections. The BV500 program aims to develop a potential best-in-class medicine for NTM infections affecting approximately 250,000 patients per year, predominantly in North America and Asia.
BioVersys (搜索) received a CHF 5 million upfront payment from Shionogi (搜索) and is eligible for development, regulatory, and sales milestones of up to CHF 479 million, plus royalties on future sales.
Tuberculosis Program Advances with GSK Partnership
The company's alpibectir program, developed in combination with ethionamide under partnership with GSK, continues to progress. GSK initiated a Phase 2 early bactericidal activity trial for the combination in pulmonary tuberculosis (搜索) in the first quarter of 2025. The trial is conducted within UNITE4TB, a European Union and European Pharmaceutical funded Innovative Medicines Initiative joint undertaking, with topline data for the first part expected by the second quarter of 2026.
Alpibectir was granted Orphan Designation by the EMA Committee for Orphan Medicinal Products in 2025, following earlier Orphan Drug Designation by the US FDA. A Phase 2 trial in meningeal tuberculosis (搜索), to be conducted by BioVersys (搜索) with a French and African academic consortium, is planned to initiate in 2026.
Addressing Critical Unmet Medical Need
BioVersys (搜索) focuses on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant bacteria. The company's candidates are designed to overcome resistance mechanisms, block virulence production, and directly affect the pathogenesis of harmful bacteria, addressing the high unmet medical need for new treatments against life-threatening resistant bacterial infections.
"2025 has been a year of significant achievements and progress for BioVersys (搜索)," said Dr. Marc Gitzinger, Chief Executive Officer. "Our IPO early in the year strengthened our financial position, enabling us to deliver multiple value-generating milestones over the next two years towards our first drug approval. The clinical development of our lead asset BV100 is going ahead as planned, with the Phase 3 now started and expecting to dose the first patients in the next few months."